Literature DB >> 29780628

Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules.

Mingzhi Ye1,2,3,4,5, Shiyong Li1,4, Weizhe Huang2, Chunli Wang6,7, Liping Liu2, Jun Liu6,7, Jilong Liu1, Hui Pan2, Qiuhua Deng2, Hailing Tang2, Long Jiang2, Weizhe Huang2, Xi Chen6,7, Di Shao1, Zhiyu Peng4, Renhua Wu6,7, Jing Zhong4, Zhe Wang4, Xiaoping Zhang4, Karsten Kristiansen5, Jian Wang4, Ye Yin4, Mao Mao4, Jianxing He2, Wenhua Liang2.   

Abstract

BACKGROUND: A non-invasive method to predict the malignancy of surgery-candidate solitary pulmonary nodules (SPN) is urgently needed.
METHODS: Super-depth next generation sequencing (NGS) of 35 paired tissues and plasma DNA was performed as an attempt to develop an early diagnosis approach.
RESULTS: Only ~6% of malignant nodule patients had driver mutations in the circulating tumour DNA (ctDNA) with >10,000-fold sequencing depth, and the concordance of mutation between tDNA and ctDNA was 3.9%. The first innovative whole mutation scored model in this study predicted 33.3% of malignant SPN with 100% specificity.
CONCLUSIONS: These results showed that lung cancer gene-targeted deep capture sequencing is not efficient enough to achieve ideal sensitivity by simply increasing the sequencing depth of ctDNA from early candidates. The sequencing could not be evaluated hotspot mutations in the early tumour stage. Nevertheless, a larger cohort is required to optimize this model, and more techniques may be incorporated to benefit the SPN high-risk population.

Entities:  

Keywords:  Solid pulmonary nodule; circulating tumour DNA (ctDNA); early diagnosis; lung cancer; tumor mutational burden (TMB)

Year:  2018        PMID: 29780628      PMCID: PMC5945686          DOI: 10.21037/jtd.2018.04.09

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  30 in total

1.  CREST maps somatic structural variation in cancer genomes with base-pair resolution.

Authors:  Jianmin Wang; Charles G Mullighan; John Easton; Stefan Roberts; Sue L Heatley; Jing Ma; Michael C Rusch; Ken Chen; Christopher C Harris; Li Ding; Linda Holmfeldt; Debbie Payne-Turner; Xian Fan; Lei Wei; David Zhao; John C Obenauer; Clayton Naeve; Elaine R Mardis; Richard K Wilson; James R Downing; Jinghui Zhang
Journal:  Nat Methods       Date:  2011-06-12       Impact factor: 28.547

Review 2.  Circulating tumor DNA as a liquid biopsy for cancer.

Authors:  Ellen Heitzer; Peter Ulz; Jochen B Geigl
Journal:  Clin Chem       Date:  2014-11-11       Impact factor: 8.327

3.  Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.

Authors:  Adam Szpechcinski; Piotr Rudzinski; Wlodzimierz Kupis; Renata Langfort; Tadeusz Orlowski; Joanna Chorostowska-Wynimko
Journal:  Cancer Lett       Date:  2016-02-05       Impact factor: 8.679

4.  Early Lung Cancer Action Project: overall design and findings from baseline screening.

Authors:  C I Henschke; D I McCauley; D F Yankelevitz; D P Naidich; G McGuinness; O S Miettinen; D M Libby; M W Pasmantier; J Koizumi; N K Altorki; J P Smith
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

5.  Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors:  Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

6.  Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma.

Authors:  Shiyong Li; Yoon-La Choi; Zhuolin Gong; Xiao Liu; Maruja Lira; Zhengyan Kan; Ensel Oh; Jian Wang; Jason C Ting; Xiangsheng Ye; Christoph Reinhart; Xiaoqiao Liu; Yunfei Pei; Wei Zhou; Ronghua Chen; Shijun Fu; Gang Jin; Awei Jiang; Julio Fernandez; James Hardwick; Min Woong Kang; Hoseok I; Hancheng Zheng; Jhingook Kim; Mao Mao
Journal:  J Thorac Oncol       Date:  2016-09-09       Impact factor: 15.609

7.  Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.

Authors:  Song Xu; Feng Lou; Yi Wu; Da-Qiang Sun; Jing-Bo Zhang; Wei Chen; Hua Ye; Jing-Hao Liu; Sen Wei; Ming-Yu Zhao; Wen-Jun Wu; Xue-Xia Su; Rong Shi; Lindsey Jones; Xue F Huang; Si-Yi Chen; Jun Chen
Journal:  Cancer Lett       Date:  2015-11-12       Impact factor: 8.679

8.  Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer.

Authors:  Johannes F Fahrmann; Dmitry Grapov; Brian C DeFelice; Sandra Taylor; Kyoungmi Kim; Karen Kelly; William R Wikoff; Harvey Pass; William N Rom; Oliver Fiehn; Suzanne Miyamoto
Journal:  Cancer Biomark       Date:  2016-03-11       Impact factor: 4.388

9.  Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.

Authors:  Zhengyan Kan; Hancheng Zheng; Xiao Liu; Shuyu Li; Thomas D Barber; Zhuolin Gong; Huan Gao; Ke Hao; Melinda D Willard; Jiangchun Xu; Robert Hauptschein; Paul A Rejto; Julio Fernandez; Guan Wang; Qinghui Zhang; Bo Wang; Ronghua Chen; Jian Wang; Nikki P Lee; Wei Zhou; Zhao Lin; Zhiyu Peng; Kang Yi; Shengpei Chen; Lin Li; Xiaomei Fan; Jie Yang; Rui Ye; Jia Ju; Kai Wang; Heather Estrella; Shibing Deng; Ping Wei; Ming Qiu; Isabella H Wulur; Jiangang Liu; Mariam E Ehsani; Chunsheng Zhang; Andrey Loboda; Wing Kin Sung; Amit Aggarwal; Ronnie T Poon; Sheung Tat Fan; Jun Wang; James Hardwick; Christoph Reinhard; Hongyue Dai; Yingrui Li; John M Luk; Mao Mao
Journal:  Genome Res       Date:  2013-06-20       Impact factor: 9.043

10.  A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma.

Authors:  Di Shao; Yongping Lin; Jilong Liu; Liang Wan; Zu Liu; Shaomin Cheng; Lingna Fei; Rongqing Deng; Jian Wang; Xi Chen; Liping Liu; Xia Gu; Wenhua Liang; Ping He; Jun Wang; Mingzhi Ye; Jianxing He
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379

View more
  6 in total

Review 1.  The Role of Radiomics in Lung Cancer: From Screening to Treatment and Follow-Up.

Authors:  Radouane El Ayachy; Nicolas Giraud; Paul Giraud; Catherine Durdux; Philippe Giraud; Anita Burgun; Jean Emmanuel Bibault
Journal:  Front Oncol       Date:  2021-05-05       Impact factor: 6.244

2.  Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.

Authors:  Xiaoxiao Wang; Cheng Kong; Weizhang Xu; Sheng Yang; Dan Shi; Jingyuan Zhang; Mulong Du; Siwei Wang; Yongkang Bai; Te Zhang; Zeng Chen; Zhifei Ma; Jie Wang; Gaochao Dong; Mengting Sun; Rong Yin; Feng Chen
Journal:  Thorac Cancer       Date:  2019-08-14       Impact factor: 3.500

3.  Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA.

Authors:  Muyun Peng; Yuancai Xie; Xiaohua Li; Youhui Qian; Xiaonian Tu; Xumei Yao; Fangsheng Cheng; Feiyue Xu; Deju Kong; Bing He; Chaoyu Liu; Fengjun Cao; Haoxian Yang; Fenglei Yu; Chuanbo Xu; Geng Tian
Journal:  J Med Genet       Date:  2019-04-13       Impact factor: 6.318

4.  PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.

Authors:  Jianping Xu; Yue Pu; Rui Lin; Shanshan Xiao; Yingxue Fu; Tao Wang
Journal:  Front Med (Lausanne)       Date:  2022-03-03

5.  The mSHOX2 is capable of assessing the therapeutic effect and predicting the prognosis of stage IV lung cancer.

Authors:  Xiumei Peng; Xiaoliang Liu; Long Xu; Yuemin Li; Huaiqing Wang; Lele Song; Wenhua Xiao
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

Review 6.  The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer.

Authors:  Cláudia Freitas; Catarina Sousa; Francisco Machado; Mariana Serino; Vanessa Santos; Natália Cruz-Martins; Armando Teixeira; António Cunha; Tania Pereira; Hélder P Oliveira; José Luís Costa; Venceslau Hespanhol
Journal:  Front Oncol       Date:  2021-04-16       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.